1119 related articles for article (PubMed ID: 17339853)
1. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
2. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
4. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
5. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
6. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
Ryan BM; Russel MG; Langholz E; Stockbrugger RW
Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
10. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
11. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
Stange EF
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
[TBL] [Abstract][Full Text] [Related]
12. Sulfasalazine and 5-ASA compounds.
Allgayer H
Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
[TBL] [Abstract][Full Text] [Related]
13. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
Kreisel W; Wolf LM; Grotz W; Grieshaber M
Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological bases of therapy with 5-ASA].
Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
[No Abstract] [Full Text] [Related]
15. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
17. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
18. Pancreatitis in inflammatory bowel diseases.
Pitchumoni CS; Rubin A; Das K
J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199
[TBL] [Abstract][Full Text] [Related]
19. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
Lauritsen K
Dan Med Bull; 1989 Sep; 36(4):378-93. PubMed ID: 2572403
[No Abstract] [Full Text] [Related]
20. [Mesalazine].
Engelhardt K; Mohr K
Dtsch Med Wochenschr; 1995 May; 120(21):769-70. PubMed ID: 7781502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
